Comparison of therapeutic effects of Azitromaycin and cotrimoxazole in patients with ocular toxoplasmosis .

Comparison of therapeutic effects of Azitromaycin and Cotrimoxazole in patients with ocular Toxoplasmosis .

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201401299820N5

Enrollment

Registered

2014-03-11

Start date

2013-10-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ocular toxoplasmosis. Toxoplasma Oculopathy

Interventions

Intervention 1: Cotrimoxazole Tablet 800 mg , bid for 6-12 weeks, Tablet Folic Acid 1 mg daily for 6-12 weeks , Tablet Prednisolon 50 mg from third day to 2 weeks. Intervention 2: Cap Azithromycin 500

Treatment - Drugs

Cotrimoxazole Tablet 800 mg , bid for 6-12 weeks, Tablet Folic Acid 1 mg daily for 6-12 weeks , Tablet Prednisolon 50 mg from third day to 2 weeks.

Cap Azithromycin 500 mg first day, then 250 mg daily, and Prednisolon tab 50 mg daily from third day to 2 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with diagnosis of ocular toxoplasmosis with positive serologic test; patients older than 16 years old; no underline diseases(such as diabetic retinopathy or uveitis). Exclusion criteria: patients under 16 years old; any related systemic or ocular diseases in particular immunodeficiency diseases.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Sharpening of Lesion Border. Timepoint: 0, weeks 3 to 4, end of treatment. Method of measurement: Clinical Examination, Fundus Photography.;Lesion Size. Timepoint: 0, weeks 3 to 4, end of treatment. Method of measurement: Autoflurescence, Infrared (Image J).;Drug Side Effects. Timepoint: 0, weeks 3 to 4, end of treatment. Method of measurement: CBC diff, Billi (T, D).;Response to Treatment. Timepoint: weeks 3 - 4. Method of measurement: Clinical Examination.;Vissual Improvment. Timepoint: 0, weeks 3 to 4, end of treatment. Method of measurement: Snellen chart.	—

Measure

Time frame

Sharpening of Lesion Border. Timepoint: 0, weeks 3 to 4, end of treatment. Method of measurement: Clinical Examination, Fundus Photography.;Lesion Size. Timepoint: 0, weeks 3 to 4, end of treatment. Method of measurement: Autoflurescence, Infrared (Image J).;Drug Side Effects. Timepoint: 0, weeks 3 to 4, end of treatment. Method of measurement: CBC diff, Billi (T, D).;Response to Treatment. Timepoint: weeks 3 - 4. Method of measurement: Clinical Examination.;Vissual Improvment. Timepoint: 0, weeks 3 to 4, end of treatment. Method of measurement: Snellen chart.

—

Secondary

Measure	Time frame
Intera ocular Pressure. Timepoint: weeks 0,2 and end of treatment. Method of measurement: goldman tonometery.;Vitritis. Timepoint: weeks 0,2 and end of treatment. Method of measurement: fundus photography and clinical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Najaf Parandin

Farabi Eye Hospital

najafparandin@yahoo.com+98 21 5542 4261

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026